Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis.
about
Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and humanGenetically modified mouse models for the study of nonalcoholic fatty liver diseaseRole of diet on non-alcoholic fatty liver disease: An updated narrative reviewMitochondrial Trifunctional Protein Defects: Clinical Implications and Therapeutic ApproachesPeroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease.Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis.Sex-different hepaticglycogen content and glucose output in rats.PPARalpha: energy combustion, hypolipidemia, inflammation and cancerSteatosis and steatohepatitis in postmortem material from Northwestern GreeceSonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adultsHepatic β-oxidation and regulation of carnitine palmitoyltransferase (CPT) I in blunt snout bream Megalobrama amblycephala fed a high fat dietProgressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice.PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchPathogenesis and management issues for non-alcoholic fatty liver diseaseFish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice.Proteomics Analysis to Identify and Characterize the Molecular Signatures of Hepatic Steatosis in Ovariectomized Rats as a Model of Postmenopausal StatusAdvances in the treatment of nonalcoholic fatty liver disease.Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A.Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitisPeroxisome proliferator-activated receptor targets for the treatment of metabolic diseasesHumanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessmentAnimal models of non-alcoholic fatty liver disease: current perspectives and recent advances.Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention.Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis.The interaction between HCV and nuclear receptor-mediated pathwaysThe Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury.Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools.Nuclear receptors and nonalcoholic fatty liver disease.Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation.Sex specific differences in hepatic and plasma lipid profiles in healthy cats pre and post spaying and neutering: relationship with feline hepatic lipidosisComparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet.PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury.Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines.Peroxisome proliferator-activated receptor alpha target genes.An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension.Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors.Prebiotic and Synbiotic Modifications of Beta Oxidation and Lipogenic Gene Expression after Experimental Hypercholesterolemia in Rat Liver.Structure and Functional Analysis of Promoters from Two Liver Isoforms of CPT I in Grass Carp Ctenopharyngodon idella.
P2860
Q21562369-B3204A32-1C6E-4F4F-8AAB-262B691CED0AQ26865248-577419C1-C08A-449B-8F2F-35761DFCBF4BQ27000333-97B45D21-55B7-4535-92DC-71CE48A71699Q28972544-5CDC9BA0-9EC4-40FF-8850-F29D6B26F4C3Q33202380-1A6143F8-7138-4EC4-A464-9C3C4AB7D0ACQ33415297-F49B91A9-C761-4929-BEB6-169CAFA4B217Q33701025-B9999BBF-2059-450C-ADD2-4DCADE74EEECQ33805104-D3D5598C-2B95-4A01-921F-0A9F891BC463Q34073625-9540CDA8-A5C4-4641-A74C-E7A4A43B18CCQ34112196-EF351F12-52AA-485F-8A62-ADDC88742F3EQ35133741-8AD19F5D-9A37-4C3A-BFF1-6B95E2ECFC8DQ35168082-30061629-2720-4642-BB1F-93F77B941087Q35568081-B4DEBC06-AE37-4F5B-82E1-8A8EAD6C5DD3Q36129673-B8F8D8C0-A46C-489D-9871-07F71A3A8186Q36179902-DC7A34EE-9EEC-43D6-AEE7-67B63BA6C4D0Q36213911-15418166-AA8D-48A0-86DE-01BE3F843EC4Q36246843-6274DA6B-1E8A-4D50-BBC6-B47B55CE524EQ36329908-9ECDA8E3-1477-4563-8B81-6ADF3FA2563DQ36377266-B6634C9F-C3C8-48AE-891B-5C3AE66DA074Q36503299-3F00781D-F555-4D05-9BE8-6B0DB083054BQ36818022-D158C6C4-A287-4A2E-B414-5C800785DF10Q36918509-D53CFE92-7176-48CA-94B6-41A7F3B35351Q37002739-FA833AD0-332D-4A98-A7F0-9DCA130A79ACQ37561108-0EFAA6A2-78FA-4331-8F2F-15F47120BC6FQ37564661-1123E765-C597-4691-AA86-556647D26BFAQ37575764-2BE18BCE-1562-4CA3-A651-EDBFF4E5D358Q37881205-24AAEF00-DDE9-4BB8-8AC6-DF2204339A2CQ38016858-8C27C41E-1EA1-4D2F-AF15-6F6D26114CBCQ38209324-99D12868-3B26-40C0-BCD4-70AD04D145CBQ38768048-762784C0-88A7-416D-9098-805E997411A9Q40587873-09A49E95-8C14-488F-92CA-2296BF2AD1BDQ41318206-BFBEF7F2-A713-4AAD-AE84-B633F8428BA7Q41942220-2A8D46A9-960D-4A99-8B6D-0A45F2D02B59Q41960645-D45B2B6E-B1A5-4A1B-8D75-3A3EABB9A9A3Q42322744-5324A3AF-EE80-4192-8E84-4ACAEDD56407Q42414964-8354B8A6-35D9-4AF1-B1D2-1A234B925672Q42738598-839C503F-7661-4DF4-A516-8283056FFF0DQ44255490-676C7048-CFFE-4178-BD83-4BFAA87312E9Q45399180-4617A0D0-872E-4935-9408-64449D58F122Q47145058-7A221AE6-005B-450F-B9C5-075EA53F37F3
P2860
Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@ast
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@en
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@nl
type
label
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@ast
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@en
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@nl
prefLabel
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@ast
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@en
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@nl
P2860
P1476
Nonalcoholic steatosis and ste ...... AR alpha, and steatohepatitis.
@en
P2093
P2860
P304
P356
10.1152/AJPGI.2001.281.6.G1333
P577
2001-12-01T00:00:00Z